# A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Source: https://onco.cc/trials/nct06413706/  
OnCo record `nct06413706` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abemaciclib and Temozolomide in glioma & glioblastoma, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy is a phase 2 interventional study registered as NCT06413706 by Eli Lilly and Company, with 45 participants enrolled, started 2024-10-25 and due to reach its primary completion in 2027-02. Interventions recorded: Abemaciclib and Temozolomide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06413706
- Phase: 2
- Setting: A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
- Sponsor: Eli Lilly and Company
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT06413706: https://clinicaltrials.gov/study/NCT06413706

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct06413706.json